A preclinical-to-early translational development in reproductive medicine suggests securinine, a natural alkaloid, can boost small ovarian follicle growth when delivered via intraovarian injection. The study reports that securinine mitigates inhibitory influences from the ovarian stroma, enabling improved follicle development. If reproducible in additional models and eventually human studies, the approach could offer a new lever for fertility programs targeting ovarian function. The mechanism-focused framing may also support biomarker work tied to stromal inhibition and follicle activation.